Eli Lilly and Company (LLY)
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Eli Lilly (LLY 0.13%) has produced a wide variety of treatments for various illnesses throughout its 145-year history. But this big pharma company truly took center stage over the past year or so, with the launches of two drugs that have been prescribed for a billion-dollar indication: weight loss.
How to Play LLY Stock as Zepbound Beats NVO's Wegovy in Obesity Study
The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study
LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Just because a bunch of billionaires all own the same stock doesn't necessarily mean it's a great pick for you. On the other hand, most billionaires have become and remained billionaires for a reason.
Britain drug-cost watchdog says it will recommend Lilly obesity drug
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health system over the next three years.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.
Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.
Eli Lilly Touts Upbeat Weight-Loss Drug Results
The weight-loss drug market is about to get even more crowded.
Eli Lilly's stock rises as Zepbound weight-loss drug achieves a key goal
Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
